Golodirsen Patent Expiration

Golodirsen is Used for treating Duchenne Muscular Dystrophy (DMD) in patients with a confirmed mutation amenable to exon 53 skipping. It was first introduced by Sarepta Therapeutics Inc in its drug Vyondys 53 on Dec 12, 2019.


Golodirsen Patents

Given below is the list of patents protecting Golodirsen, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Vyondys 53 US10227590 Antisense oligonucleotides for inducing exon skipping and methods of use thereof Jun 28, 2025 Sarepta Theraps Inc
Vyondys 53 US10266827 Antisense oligonucleotides for inducing exon skipping and methods of use thereof Jun 28, 2025 Sarepta Theraps Inc
Vyondys 53 US10421966 Antisense oligonucleotides for inducing exon skipping and methods of use thereof Jun 28, 2025 Sarepta Theraps Inc
Vyondys 53 US10533174 Splice-region antisense composition and method May 04, 2021

(Expired)

Sarepta Theraps Inc
Vyondys 53 US10968450 Antisense oligonucleotides for inducing exon skipping and methods of use thereof Jun 28, 2025 Sarepta Theraps Inc
Vyondys 53 US10995337 Antisense oligonucleotides for inducing exon skipping and methods of use thereof Jun 28, 2025 Sarepta Theraps Inc
Vyondys 53 US9024007 Antisense oligonucleotides for inducing exon skipping and methods of use thereof Jun 28, 2025 Sarepta Theraps Inc
Vyondys 53 US9416361 Splice-region antisense composition and method May 04, 2021

(Expired)

Sarepta Theraps Inc
Vyondys 53 US9994851 Antisense oligonucleotides for inducing exon skipping and methods of use thereof Jun 28, 2025 Sarepta Theraps Inc
Vyondys 53 USRE47691 Antisense oligonucleotides for inducing exon skipping and methods of use thereof Jun 28, 2028 Sarepta Theraps Inc


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Golodirsen's patents.

Given below is the list recent legal activities going on the following patents of Golodirsen.

Event Date Patent/Publication
Patent litigations
Withdrawal of Application for PTE 07 Mar, 2024 US9024007
Withdrawal of Application for PTE 07 Mar, 2024 US10421966
Withdrawal of Application for PTE 07 Mar, 2024 US9994851
Withdrawal of Application for PTE 07 Mar, 2024 US10266827
Withdrawal of Application for PTE 07 Mar, 2024 US10227590
Notice of Final Determination -Election Required 18 Jul, 2023 US10266827
Notice of Final Determination -Election Required 18 Jul, 2023 US10421966
Notice of Final Determination -Election Required 18 Jul, 2023 US9024007
Notice of Final Determination -Election Required 18 Jul, 2023 US10227590
Notice of Final Determination -Election Required 18 Jul, 2023 US9994851



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳